Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Minerva Neurosciences (NERV) Cash & Equivalents (2016 - 2026)

Minerva Neurosciences filings provide 3 years of Cash & Equivalents readings, the most recent being $54.0 million for Q4 2021.

  • On a quarterly basis, Cash & Equivalents rose 112.97% to $54.0 million in Q4 2021 year-over-year; TTM through Dec 2021 was $54.0 million, a 112.97% increase, with the full-year FY2021 number at $54.0 million, up 112.97% from a year prior.
  • Cash & Equivalents hit $54.0 million in Q4 2021 for Minerva Neurosciences, down from $65.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $80.1 million in Q1 2021 to a low of $21.4 million in Q4 2019.
  • Median Cash & Equivalents over the past 3 years was $32.5 million (2020), compared with a mean of $46.2 million.
  • Biggest five-year swings in Cash & Equivalents: rose 18.42% in 2020 and later surged 166.81% in 2021.
  • Minerva Neurosciences' Cash & Equivalents stood at $21.4 million in 2019, then grew by 18.42% to $25.4 million in 2020, then soared by 112.97% to $54.0 million in 2021.
  • The last three reported values for Cash & Equivalents were $54.0 million (Q4 2021), $65.6 million (Q3 2021), and $74.2 million (Q2 2021) per Business Quant data.